Clinical trials located in

Gliwice

Gliwice city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Gliwice, located in southern Poland, is a city rich in history and culture. Established in the 13th century, it boasts one of the best-preserved medieval castles in Silesia. The city is also home to the Gliwice Radio Tower, the world’s tallest wooden structure, which played a pivotal role in the outbreak of World War II through the Gleiwitz incident. Gliwice’s architectural landscape is a blend of Gothic, Baroque, and modernist styles, reflecting its diverse historical influences. The city’s vibrant academic scene is anchored by the Silesian University of Technology, contributing to its reputation as a center of innovation and education.

  • CT-EU-00116791

    Study of Subcutaneous Combination Treatment for Metastatic Melanoma

    AustriaBelgiumCzechiaFinlandFranceGermanyItalyNorwayPolandSpainSwedenUnited Kingdom
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    BelgiumDenmarkFranceGermanyGreeceItalyPolandPortugalSpainSwedenUnited Kingdom
  • Comparison of adjuvant therapy for high-risk postoperative adrenocortical carcinoma

    The ADIUVO-2 Trial is a phase III clinical study designed to explore the best treatment approach for patients with Stage I-III Adrenocortical Cancer that has a high risk of returning after surgery. This trial is comparing two different treatment methods to see which one is more effective in preventing the cancer from coming back.

    One group of patients will receive a medication called mitotane by itself, which is known to reduce the amount of cortisol, a substance that can promote the growth of adrenocortical tumor cells. The other group will receive mitotane along with two chemotherapy drugs, cisplatin and etoposide, which work in various ways to stop tumor cells from growing or spreading.

    The main goal of this study is to see which treatment option better prevents the cancer from returning. This is measured by the time patients remain free from cancer recurrence. Additionally, the study will look at the overall survival of patients, how different factors like the level of mitotane in the blood, the stage of the disease, and how well the surgery went might influence the outcomes.

    The trial also aims to understand the impact of starting the treatment early (1-6 weeks after surgery) versus later (more than 6 weeks after surgery) on patient outcomes. Moreover, it will monitor any serious side effects and assess the quality of life of participants throughout the study using a specific questionnaire.

    For those interested in the more scientific aspects, the study will also perform molecular profiling on tumor samples to identify any genetic changes that might be linked to how well patients respond to the treatment or the likelihood of the cancer coming back.

    Participants in the study will be randomly assigned to one of the two treatment groups. Those in the first group will take mitotane daily for up to 2 years unless the cancer progresses or they experience unacceptable side effects. Those in the second group will take mitotane in the same way but will also receive cisplatin and etoposide through an IV for up to 4 cycles, each cycle lasting 21 days, unless the cancer progresses or they experience unacceptable side effects.

    After completing the treatment, patients will be followed up every 6 months to monitor their health and any signs of cancer recurrence.

    FrancePoland
  • Discovering pembrolizumab for the treatment of advanced adrenocortical carcinoma

    This clinical trial is focused on exploring the effectiveness and safety of a medication called pembrolizumab, also known by its brand name Keytruda, in treating patients with a rare and aggressive type of cancer known as adrenocortical carcinoma. This cancer affects the adrenal glands located above the kidneys and has limited treatment options, especially in its advanced stages.

    The study is being conducted across multiple centers and is open to adults over 18 years old who have this type of cancer that has progressed despite receiving first-line chemotherapy treatments, specifically the EDP or EDP-M regimen, within the past 6 months. The treatment in this trial involves receiving pembrolizumab through an IV every three weeks at a dose of 200 mg. For those whose tumors are producing cortisol, additional medications like metyrapone or ketoconazole will be used to enhance the effectiveness of the immunotherapy.

    The main goal of this study is to see how well pembrolizumab works in treating this cancer, measured by the objective response rate, which looks at how much the cancer has shrunk or if it has disappeared after treatment. Other important aspects being looked at include how long patients live without their cancer getting worse, how long the benefits of the treatment last, overall survival, safety of the treatment, and its impact on the quality of life.

    This trial represents a hope for patients with advanced adrenocortical carcinoma, offering a potential new treatment option after other therapies have failed. It’s a significant step towards understanding and potentially improving the management of this challenging condition.

    Poland
  • A study of relacorilant in the treatment of hypercortisolism (Cushing’s syndrome) in patients with adrenal adenoma

    This clinical trial focuses on testing the effectiveness and safety of a drug called relacorilant in the treatment of patients with hypercortisolism (Cushing’s syndrome). Hypercortisolism is a condition in which there is too much cortisol in the body, which may occur due to an adenoma or hyperplasia of the adrenal glands that secrete cortisol. This condition can lead to diabetes or impaired glucose tolerance and/or uncontrolled high blood pressure.

    The study is in phase III, which means that the effectiveness and safety of the drug are compared with placebo. This is a double-blind, placebo-controlled study, which means neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo to ensure unbiased results.

    Participants in this study will be randomly assigned to receive relacorilant or placebo for 22 weeks. The main goals of the study are to see how well relakorilant can improve blood sugar levels in patients with diabetes or impaired glucose tolerance, and how it affects blood pressure in people with high blood pressure. Additionally, the study will monitor the safety of relacorilant by recording any adverse events that occur.

    People who complete the study may have the opportunity to continue with a follow-up study, which may provide further information on the long-term effects and benefits of relacorilant.

    AustriaBulgariaGermanyItalyPolandRomaniaSpain
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalSpainSwedenUnited Kingdom
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryNetherlandsNorwayPolandSwedenUnited Kingdom
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    AustriaBelgiumFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    AustriaBelgiumCzechiaFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    BelgiumFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Evaluating two drug combinations for advanced breast cancer

    This study is examining two different drug combinations for treating a specific type of breast cancer. The primary aim is to assess the comparative effectiveness and safety of these combinations. One combination uses the drugs lasofoxifene and abemaciclib, and the other uses fulvestrant and abemaciclib. The patients for this trial are men and women who have already been treated for breast cancer that has spread or cannot be removed by surgery, is positive for estrogen receptors (ER+), does not over-produce a growth factor (HER2-), and has a specific genetic mutation (ESR1).

    BelgiumCzechiaFranceGermanyHungaryItalyPolandRomaniaSpainUnited Kingdom
  • Comparing idecabtagene vicleucel and lenalidomide therapy for Multiple Myeloma

    This study involves the comparison of two treatments to assess their effectiveness, safety, and tolerability in adults with multiple myeloma who did not achieve complete recovery after a stem cell transplant. One treatment, referred to as ‘ide-cel’ (idecabtagene vicleucel), is administered in combination with another medication called lenalidomide. The alternative treatment involves the use of lenalidomide alone. The study is an open experiment, meaning the assigned treatment is known. The primary objectives include evaluating the efficacy of the treatments, assessing their safety, and gauging the participants’ tolerance. Additionally, the study will monitor general well-being, considering factors such as strength, fatigue, pain, and any symptoms or side effects experienced.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNorwayPolandRomaniaSpainUnited Kingdom
  • Study on new immunotherapy combinations for throat and neck cancer treatment

    This study evaluated advanced immunotherapeutic treatments for PD-L1-positive head and neck squamous cell carcinoma. The study involves comparing innovative combinations of immunotherapy with dostarlimab monotherapy to select the most effective treatment method. It focuses on patients with recurrent or metastatic cancer and aims to improve survival rates and response to treatment.

    DenmarkFinlandFranceGermanyGreeceHungaryItalyNorwayPolandPortugalRomaniaSpainSweden
  • Study on new therapy for advanced solid tumors treatment

    This clinical trial investigates Datopotamab Deruxtecan (Dato-DXd), alone or combined with other anti-cancer drugs, in adults with various advanced solid tumors. The study aims to evaluate the safety, tolerability, and effectiveness of Dato-DXd in treating cancers like endometrial, gastric, prostate, ovarian, colorectal, urothelial, and biliary tract cancer. Participants will receive Dato-DXd as monotherapy or in combination, depending on the specific cancer subtype. The study’s primary focus is on assessing the treatment’s response rate and monitoring for any potential side effects. This trial offers a promising avenue for those with advanced cancers seeking new treatment options.

    FranceItalyPolandSpainUnited Kingdom
  • Study of the effects of Durvalumab and Domvanalimab on non-small cell lung cancer

    This study looks at two drugs – Durvalumab and Domvanalimab – and how they may help people with a type of lung cancer that cannot be removed by surgery. These medicines are given to patients after special treatment combining chemotherapy and radiotherapy. The goal is to find out whether these drugs provide benefits and are safe to use. During the trial, patients will be given the real drug or a placebo (a substance that has no therapeutic effect), without knowing which one they will receive. The study will measure how long it takes for the disease to worsen, how long people live and how many people respond positively to treatment. This clinical trial is testing the effectiveness of Durvalumab and Domvanalimab – two drugs – in the treatment of stage III lung cancer that cannot be surgically removed. After undergoing chemotherapy and radiation therapy, participants will be given these drugs to assess their safety. The study is double-blind, meaning neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo. The study will monitor whether the cancer gets worse and what the rate of positive reactions to the drugs is. A study is being conducted with two drugs, Durvalumab and Domvanalimab, for patients with advanced forms of lung cancer that cannot be treated with surgery. After undergoing combined chemotherapy and radiation therapy, participants receive these drugs. The study was designed so that neither the patient nor the doctor knew whether the correct drug or a placebo was being administered. The time until the disease worsens, how long participants live and the number of patients who see improvement with the drugs will be measured.

    BelgiumFranceGermanyGreeceHungaryItalyNorwayPolandRomaniaSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • The effectiveness of the drug cemiplimab in patients with cutaneous squamous cell carcinoma

    The scope of this research investigation is to study the effects of a drug, cemiplimab, given after surgery and radiation therapy in patients with a high risk of skin cancer recurrence. Cemiplimab is a type of antibody medication that targets proteins involved in cancer. It boosts the immune system to fight cancer cells more effectively. The major focus of this study is to understand if this drug can prevent the return of cutaneous squamous cell cancer post-surgery and radiation. Currently, there’s no confirmed treatment to stop high-risk cancers from coming back after surgery and radiation. Investigating cemiplimab may help us find a solution to this issue. The study involves two parts: in part 1, participants will receive either the study drug or placebo through an intravenous infusion periodically. This part includes a treatment period and follow-up session. Part 2 is optional and presents a possibility for the participant to receive the study drug if the cancer reoccurs.

    BelgiumFranceGermanyGreeceItalyPolandSpainUnited Kingdom

See more clinical trials in other cities in Poland:

.